887307-13-3

Upstream product

• 887307-12-2 ethyl 1-(2,6-dichlorophenyl)-6-oxo-1,6-dihydropyridine-3-carboxylate 

Downstream Products

• 1082294-38-9 N-{5-[({[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino}carbonyl)amino]-2-methylphenyl}-1-(2,6-dichlorophenyl)-6-oxo-1,6-dihydro-3-pyridinecarboxamide 
• 1082294-34-5 N-{5-[(cyclopropylcarbonyl)amino]-2-methylphenyl}-1-(2,6-dichlorophenyl)-6-oxo-1,6-dihydro-3-pyridinecarboxamide 
• 1082294-22-1 N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-1-(2,6-dichlorophenyl)-6-oxo-1,6-dihydro-3-pyridinecarboxamide 
• 1191545-52-4 1-(2,6-dichlorophenyl)-6-oxo-1,6-dihydropyridine-3-carbonylchloride 

Relevant academic research and scientific papers

NEW COMPOUNDS

A compound represented by the formula (I): wherein R1 is lower alkyl, cycloalkyl or aromatic hydrocarbon ring, each of which is optionally substituted with one or more substituents; R2 is hydrogen atom, halogen atom, lower alkyl, hal

NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention relates to a compound that has p38 MAP kinase inhibitory activity useful as drug medicine, represented by the general formula (I) : wherein all the symbols are as defined in the description, or itssalt, N-oxide or solvate, or a prodrug thereof. Further, there are provided a process for producing the same and usage thereof. The compound of the general formula (I) has a p38 MAP kinase inhibory activity and is useful for the prevention and/or treatment of diseases in which an abnormal production of cytokine, such as inflammatory cytokine or chemokine, or an over-reaction thereto would be instrumental in the cause and aggravation of pathologic condition thereof, namely, cytokine-mediated diseases, for example, inflammatory diseases, respiratory diseases, circulatory diseases, central nervous diseases, etc.